BAM
MYGN icon

Byrne Asset Management’s Myriad Genetics MYGN Stock Holding History

Byrne Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$444 – 578
2025
Q1 		$444 Hold
50
– – ﹤0.01% 545
2024
Q4 		$686 Sell
50
-200
-80% -$3.69K ﹤0.01% 524
2024
Q3 		$6.85K Hold
250
– – ﹤0.01% 432
2024
Q2 		$6.08K Hold
250
– – ﹤0.01% 429
2024
Q1 		$5.33K Hold
250
– – ﹤0.01% 429
2023
Q4 		$4.95K Sell
250
-250
-50% -$4.33K ﹤0.01% 416
2023
Q3 		$8K Hold
500
– – 0.01% 362
2023
Q2 		$12K Buy
+500
New +$10.9K 0.01% 382

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Byrne Asset Management's MYGN Position: Q2 2025 in Review

Byrne Asset Management sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 50 shares — an estimated $444 sold.

Byrne Asset Management first reported a position in MYGN in Q2 2023 and held it in 8 quarters. The position peaked at $12K in Q2 2023. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Byrne Asset Management reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Byrne Asset Management sold 50 Myriad Genetics shares in Q2 2025, an estimated $444.
  • Byrne Asset Management first reported a position in Myriad Genetics in Q2 2023 and held it in 8 quarters.
  • Byrne Asset Management's Myriad Genetics position peaked at $12K in Q2 2023.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Byrne Asset Management's 13F filing for Q2 2025, filed 9 Jul 2025.